5-alpha reductase inhibitor
Dutasteride
The Avodart label gives dutasteride's terminal elimination half-life as approximately 5 weeks at steady state, which matches the app's 840 hours (35 days).1
Dutasteride after one dose: 50% at ~840 h, 25% at 1680 h, 12.5% at 2520 h.
Drawn from the half-life in the app's model, ~840 h. The model's figures
- Compound
- Dutasteride
- Symbol
- DUT
- Family
- Supplements
- Parts
- 14
- References
- 10
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
Dutasteride is a 5 alpha-reductase inhibitor; the US Avodart label describes it as a synthetic 4-azasteroid compound that inhibits both the type 1 and type 2 isoforms of the enzyme.1 The label lists one use, symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate, alone or with the alpha-adrenergic antagonist tamsulosin, and gives 2001 as the initial US approval year.1 Its Limitations of Use state: "AVODART is not approved for the prevention of prostate cancer."1
The app lists dutasteride as a supplement in the category 5-alpha reductase inhibitor, with a once-daily oral dose of 0.5 mg and a half-life of 840 hours. The app grades the evidence as strong; that is the app's grade and not a conclusion of the sources cited here.
How it works
Sources in this part
The label states that dutasteride "is a competitive and specific inhibitor of both type 1 and type 2 5 alpha-reductase isoenzymes, with which it forms a stable enzyme complex", and that dissociation from this complex "is extremely slow".1 The label says the type 2 isoenzyme is primarily active in the reproductive tissues, while the type 1 isoenzyme is also responsible for testosterone conversion in the skin and liver.1 In the 2014 hair-loss trial the authors describe dutasteride as a "type 1 and 2 5-alpha reductase inhibitor" and finasteride as a "type 2 5-alpha reductase inhibitor".2 On 0.5 mg daily the label reports median serum dihydrotestosterone (DHT) reductions of 85% after 1 week and 90% after 2 weeks.1 In men with BPH on 0.5 mg daily for 4 years, the median decrease was 94% at 1 year, 93% at 2 years and 95% at both 3 and 4 years, with median serum testosterone up 19% at 1 and 2 years, 26% at 3 years and 22% at 4 years, which the label says remained within the physiologic range.1 In a separate label-described trial of men with BPH given 5 mg/day (ten times the label dose) or placebo for up to 12 weeks before prostate surgery, mean prostatic tissue DHT was 784 pg/g with dutasteride and 5,793 pg/g with placebo (P below 0.001).1
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~840 h
- Bioavailability
- 60%
- Typical dose
- 0.5 mg/day
- Route
- Oral
- Time to peak
- ~2.5 h
Sources in this part
The second column of the table holds the app's own figures, shown beside what the Avodart label reports.
| Parameter | App's figure | Avodart label |
|---|---|---|
| Half-life | ~840 h (35 days) | Terminal elimination half-life of approximately 5 weeks at steady state; in a single-dose trial of 36 healthy men aged 24 to 87 given 5 mg, approximately 170 hours at ages 20 to 49, 260 hours at 50 to 69 and 300 hours above 701 |
| Bioavailability | 60% | Absolute bioavailability approximately 60% (range 40% to 94%) in 5 healthy subjects after a single 0.5 mg soft gelatin capsule; with food, maximum serum concentrations were reduced by 10% to 15%1 |
| Time to peak | ~2.5 h | Peak serum concentration within 2 to 3 hours of a single 0.5 mg capsule1 |
| Duration | 1,680 h (70 days) | Serum concentrations remain detectable (greater than 0.1 ng/mL) for up to 4 to 6 months after stopping1 |
| Approach to steady state | Not in the app's figures | 65% of steady-state concentration after 1 month and approximately 90% after 3 months of daily dosing; average steady-state serum concentration 40 ng/mL after 0.5 mg/day for 1 year1 |
| Distribution | Not in the app's figures | Volume of distribution 300 to 500 L; 99.0% bound to plasma albumin and 96.6% to alpha-1 acid glycoprotein1 |
| Metabolism and excretion | Not in the app's figures | Metabolised in vitro by CYP3A4 and CYP3A5; excreted mainly in feces, about 5% of the dose as unchanged dutasteride and 40% as dutasteride-related metabolites1 |
The label also reports that, in healthy subjects on 0.5 mg/day for 12 months, semen dutasteride averaged 3.4 ng/mL (range 0.4 to 14 ng/mL) and about 11.5% of serum dutasteride concentrations partitioned into semen.1 The label says the effect of hepatic impairment on dutasteride pharmacokinetics has not been studied and that exposure could be higher because dutasteride is extensively metabolised.1
Level over 6 weeks
Level, as a share of the peak after one 100 mg dose
As studied: once daily, the label dose1.
An illustration from a pharmacokinetic model using a half-life of 840 hours (35 days). It is not a measured level or a suggested dose.
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Andriole and colleagues, REDUCE, New England Journal of Medicine 20103,4 | Multicenter, randomised, double-blind, placebo-controlled; registry lead sponsor GlaxoSmithKline3,4 | Men aged 50 to 75 with PSA 2.5 to 10.0 ng/mL and one negative prostate biopsy in the prior 6 months; 8231 enrolled in the registry, 6729 with a biopsy or prostate surgery in the analysis3,4 | Dutasteride 0.5 mg daily or placebo; 4 years3 | Cancer detected in 659 of 3305 (dutasteride) against 858 of 3424 (placebo), relative risk reduction 22.8% (95% CI 15.2 to 29.8); Gleason 7 to 10 tumours 220 against 233 (P=0.81); Gleason 8 to 10 in years 3 and 4, 12 against 1 (P=0.003); cardiac failure 0.7% against 0.4% (P=0.03)3 |
| Roehrborn and colleagues, CombAT, European Urology 20105,6 | Multicenter, randomised, double-blind, parallel-group, no placebo arm; registry lead sponsor GlaxoSmithKline5,6 | 4844 men aged 50 or older with BPH, International Prostate Symptom Score of 12 or more, prostate volume of 30 cm3 or more5 | Tamsulosin 0.4 mg, dutasteride 0.5 mg or both, daily; 4 years5 | Combination superior to tamsulosin but not to dutasteride alone for acute urinary retention or BPH-related surgery; superior to both for BPH clinical progression; imbalance in cardiac failure across the arms5 |
| Gubelin Harcha and colleagues, Journal of the American Academy of Dermatology 20142,7 | Multicenter, randomised, double-blind, active- and placebo-controlled; sponsor GlaxoSmithKline, three authors at GlaxoSmithKline2,7 | 917 men aged 20 to 50 with androgenetic alopecia2 | Dutasteride 0.02, 0.1 or 0.5 mg/day, finasteride 1 mg/day or placebo; 24 weeks2 | Hair count change at week 24 (registry least-squares mean) -4.9 with placebo, 17.1, 63.0 and 89.6 with dutasteride 0.02, 0.1 and 0.5 mg, 56.5 with finasteride; dutasteride 0.5 mg ahead of finasteride (P = .003)2,7 |
| Olsen and colleagues, Journal of the American Academy of Dermatology 20068 | Randomised, placebo-controlled; funder not stated in the record read8 | 416 men aged 21 to 45 with male pattern hair loss8 | Dutasteride 0.05, 0.1, 0.5 or 2.5 mg, finasteride 5 mg, or placebo, daily; 24 weeks8 | Dutasteride raised target area hair count against placebo in a dose-dependent fashion; 2.5 mg superior to finasteride 5 mg at 12 and 24 weeks8 |
| Lee and colleagues, Acta Dermato-Venereologica 20199 | Systematic review and meta-analysis of randomised, double-blind, placebo-controlled trials9 | 15 trials, 4,495 subjects, male androgenetic alopecia9 | Finasteride 1 mg/day or dutasteride 0.5 mg/day9 | Relative risk of sexual dysfunction 1.57 (95% CI 1.19-2.08) overall; 1.66 (1.20-2.30) for finasteride and 1.37 (0.81-2.32) for dutasteride, an increase the authors describe as not statistically significant for dutasteride; the authors note studies into dutasteride were limited9 |
The searches behind these sections were PubMed for "dutasteride randomized controlled trial" (266 records) and ClinicalTrials.gov for "dutasteride androgenetic alopecia" (12 records), both on 16 November 2026; trials of other uses, such as alcohol drinking, benign prostatic hyperplasia combinations with tadalafil and topical hair-loss products, appeared in the results and are not summarised here.
Deeper analysis: REDUCE
Andriole and colleagues reported REDUCE in the New England Journal of Medicine in 2010, a 4-year trial of dutasteride 0.5 mg daily against placebo in men at increased risk of prostate cancer, with a 10-core biopsy at 2 and 4 years.3 The registry names GlaxoSmithKline as lead sponsor and as the responsible party.4 The PubMed record lists an affiliation only for the first author (Washington University School of Medicine in St. Louis), so the authors' ties to the sponsor cannot be read from it.3 The primary comparison favoured dutasteride: cancer was detected in 659 of 3305 men on dutasteride and 858 of 3424 on placebo, a relative risk reduction of 22.8% (95% confidence interval 15.2 to 29.8, P<0.001) over the 4 years.3 The secondary and safety results were less one-sided: tumours with a Gleason score of 7 to 10 were 220 among 3299 men on dutasteride and 233 among 3407 on placebo (P=0.81), while in years 3 and 4 there were 12 tumours with a Gleason score of 8 to 10 on dutasteride "as compared with only 1 in the placebo group (P=0.003)".3 Acute urinary retention was 1.6% on dutasteride and 6.7% on placebo, and the composite category of cardiac failure was 0.7% (30 men) against 0.4% (16 men), P=0.03.3 The Avodart label reports Gleason score 8 to 10 prostate cancer in 1.0% of men on dutasteride and 0.5% on placebo in REDUCE, and cardiac failure in 26 of 4,105 (0.6%) against 15 of 4,126 (0.4%).1 The label adds that it has not been established whether the effect of 5 alpha-reductase inhibitors on prostate volume, or trial-related factors, influenced the results of these trials.1 The registry lists serious adverse events in 837 of 4126 on placebo and 748 of 4105 on dutasteride.4 The record read gives no authors' limitations section for REDUCE; the label's caution above is the nearest statement about how the findings may be read.3
Deeper analysis: CombAT
Roehrborn and colleagues reported 4-year CombAT results in European Urology in 2010: 4844 men with BPH, lower urinary tract symptoms and prostate enlargement were randomised to tamsulosin 0.4 mg, dutasteride 0.5 mg or both once daily.5 The primary end point was "time to first AUR or BPH-related surgery", where AUR is acute urinary retention.5 Combination therapy was "significantly superior to tamsulosin monotherapy but not dutasteride monotherapy" for that end point, and significantly superior to both monotherapies for BPH clinical progression.5 The authors name the lack of placebo control as a study limitation, and report an imbalance in the composite term cardiac failure across the three arms.5 The label gives cardiac failure after 4 years as 12 of 1,610 (0.7%) with combination therapy, 2 of 1,623 (0.1%) with dutasteride and 9 of 1,611 (0.6%) with tamsulosin, and states that no causal relationship between dutasteride, alone or in combination with tamsulosin, and cardiac failure has been established.1 The label also reports ejaculation disorders in 11% on combination therapy against 2% on dutasteride and 4% on tamsulosin, and trial withdrawal for adverse reactions in 6% on combination therapy and 4% on each monotherapy.1 The registry names GlaxoSmithKline as lead sponsor and lists serious adverse events in 303 of 1610 on combination, 339 of 1623 on dutasteride and 348 of 1611 on tamsulosin.6 The PubMed record lists an affiliation only for the first author (Department of Urology, UT Southwestern Medical Center), so the authors' ties to the sponsor cannot be read from it.5
Deeper analysis: the 2014 hair-loss trial
Gubelin Harcha and colleagues, whose listed affiliations are in Chile, Peru, Taiwan, Japan and the United States, reported in the Journal of the American Academy of Dermatology in 2014 a multicenter 24-week trial in which 917 men aged 20 to 50 with androgenetic alopecia received dutasteride 0.02, 0.1 or 0.5 mg/day, finasteride 1 mg/day or placebo, with hair count in a 2.54-cm diameter area at week 24 as the primary end point.2 The registry names GlaxoSmithKline as lead sponsor, and three of the nine listed authors (Barnes, Ferron-Brady and Chetty) are affiliated with GlaxoSmithKline Research & Development.7,2 The registry's primary-outcome analysis gives least-squares mean changes in hair count of -4.9 with placebo, 17.1 with dutasteride 0.02 mg, 63.0 with 0.1 mg, 89.6 with 0.5 mg and 56.5 with finasteride 1 mg.7 Dutasteride 0.5 mg against placebo gave a least-squares mean difference of 94.4 (98.33% confidence interval 67.8 to 121.0), and the authors report that 0.5 mg was ahead of finasteride on hair count, hair width and panel photographic assessment (P = .003, .004 and .002).7,2 The 0.1 mg dose was not separated from finasteride: the registry lists P 0.56 for that superiority comparison.7 The authors write that "The number and severity of adverse events were similar among treatment groups", and the registry lists serious adverse events in 0 of 185 (0.02 mg), 3 of 188 (0.1 mg), 1 of 184 (0.5 mg), 2 of 179 (finasteride) and 2 of 181 (placebo).2,7 The registry's participant flow lists 31 of 184 on dutasteride 0.5 mg, 38 of 179 on finasteride and 24 of 181 on placebo as not completing.7 The same flow lists withdrawal for adverse events in 0 of 185 on dutasteride 0.02 mg, 8 of 188 on 0.1 mg, 4 of 184 on 0.5 mg, 4 of 179 on finasteride and 5 of 181 on placebo, with 29 of 185 (0.02 mg) and 34 of 188 (0.1 mg) not completing.7 The authors state "The study was limited to 24 weeks" and conclude that dutasteride "was relatively well tolerated".2 The trial registry's own description states that dutasteride is approved "in more than 80 countries for the treatment of benign prostatic hyperplasia, and in Korea for the treatment of hair loss"; the US Avodart label's indications list no hair-loss use.7,1
Other reports: Olsen 2006 and the 2019 meta-analysis
Olsen and colleagues (Journal of the American Academy of Dermatology, 2006) randomised 416 men aged 21 to 45 to dutasteride 0.05, 0.1, 0.5 or 2.5 mg, finasteride 5 mg or placebo daily for 24 weeks; dutasteride 2.5 mg was superior to finasteride at 12 and 24 weeks, and scalp and serum DHT fell and testosterone rose dose-dependently with dutasteride.8 The record states "The study was limited to 24 weeks" and gives no funding statement or adverse event counts.8 Lee and colleagues (Acta Dermato-Venereologica, 2019) pooled 15 randomised placebo-controlled trials of finasteride 1 mg/day or dutasteride 0.5 mg/day in men with androgenetic alopecia; the relative risk of sexual dysfunction was 1.37 (95% CI 0.81-2.32) for dutasteride, which the authors describe as not statistically significant, against 1.66 (95% CI 1.20-2.30) for finasteride.9 The authors add: "As studies into dutasteride were limited, further trials are required."9
Doses reported in studies and on labels
| Source | Population | Dose and schedule | Comparator, length and n |
|---|---|---|---|
| Avodart label, monotherapy1 | Men with symptomatic BPH and an enlarged prostate | 0.5 mg (1 capsule) once daily | Label dose; pivotal trials 2 years placebo-controlled, 2,167 men exposed to dutasteride |
| Avodart label, combination1 | Men with symptomatic BPH and an enlarged prostate | 0.5 mg dutasteride and 0.4 mg tamsulosin, each once daily | Label dose; CombAT 4 years, 1,610 on combination |
| REDUCE3 | Men aged 50 to 75 with a negative biopsy and PSA 2.5 to 10.0 ng/mL | 0.5 mg daily, oral | Placebo; 4 years; 3305 against 3424 in the biopsy or surgery analysis |
| Gubelin Harcha 20142 | Men aged 20 to 50 with androgenetic alopecia | 0.02, 0.1 or 0.5 mg/day, oral | Finasteride 1 mg/day and placebo; 24 weeks; 917 randomised |
| Olsen 20068 | Men aged 21 to 45 with male pattern hair loss | 0.05, 0.1, 0.5 or 2.5 mg daily | Finasteride 5 mg and placebo; 24 weeks; 416 randomised |
| Label hepatic safety trial1 | 60 subjects | 5 mg daily, ten times the label dose | 24 weeks; no additional adverse events compared with the 0.5 mg dose |
The app's typical dose is 0.5 mg/day, the same figure as the label dose above.
Side effects reported
Sources in this part
The label states that the most common adverse reactions in men receiving dutasteride were impotence, decreased libido, breast disorders (including breast enlargement and tenderness) and ejaculation disorders.1 In the pooled 2-year placebo-controlled BPH trials, impotence in months 0 to 6 was 4.7% with dutasteride (n = 2,167) against 1.7% with placebo (n = 2,158), decreased libido 3.0% against 1.4%, ejaculation disorders 1.4% against 0.5%, and breast disorders 0.5% against 0.2%.1 Trial withdrawal due to adverse reactions occurred in 4% on dutasteride and 3% on placebo, and the most common reason was impotence (1%).1 The label states that these sexual adverse reactions may persist after treatment discontinuation and that the role of dutasteride in this persistence is unknown.1 Across the three 4-year pivotal BPH trials the label found no evidence of increased sexual or breast adverse reactions with longer treatment, and says the relationship between long-term use of dutasteride and male breast neoplasia is currently unknown.1 Post-approval reports listed on the label include hypersensitivity reactions (rash, pruritus, urticaria, localized edema, serious skin reactions, angioedema), male breast cancer, depressed mood, and testicular pain and swelling; the label notes that such reports come from "a population of uncertain size", so frequency and causality cannot always be established.1 The label lists pregnancy as a contraindication and states that women who are or may be pregnant are not to handle the capsules, because dutasteride "can be absorbed through the skin" (the label says this is based on animal studies) and could cause unintended fetal exposure and potential risk to a male fetus.1
Bloodwork and markers
Sources in this part
The label states that dutasteride reduced serum PSA by approximately 50% within 3 to 6 months in clinical trials and may also lower PSA in the presence of prostate cancer.1 For men treated for 3 months or more, the label describes doubling an isolated PSA value for comparison with normal values in untreated men, and says percent free PSA remains constant.1 In a 52-week trial of healthy volunteers on 0.5 mg/day (n = 26) against placebo (n = 23), the label reports no clinically significant change in sex hormone-binding globulin, estradiol, luteinizing hormone, follicle-stimulating hormone, free T4 or dehydroepiandrosterone, a median 17.9% rise in testosterone at 8 weeks and a median 12.4% rise in thyroid-stimulating hormone at 52 weeks; both were back at baseline 24 weeks after stopping in the subjects with data.1 In men with BPH in a large placebo-controlled trial, median luteinizing hormone rose 12% at 6 months and 19% at both 12 and 24 months.1 After 52 weeks in healthy volunteers the label reports no change in bone mineral density by dual energy x-ray absorptiometry and no effect on the plasma lipid profile.1 In 27 men on dutasteride and 23 on placebo, mean total sperm count, semen volume and sperm motility were 23%, 26% and 18% lower than baseline at 52 weeks (adjusted for placebo); total sperm count remained 23% below baseline after 24 weeks of follow-up, and the label says the clinical significance for an individual's fertility is not known.1 The label adds that mean values for all semen parameters at all timepoints remained within the normal ranges and did not meet the predefined criteria for a clinically significant change (30%), while 2 subjects in the dutasteride group had decreases in sperm count of greater than 90% from baseline at 52 weeks, with partial recovery at the 24-week follow-up.1 The label sets a blood-donation deferral of at least 6 months after the last dose.1
Regulatory and anti-doping status
Sources in this part
The Avodart label carries the initial US approval year 2001 and is held by Waylis Therapeutics LLC in the DailyMed record read.1 The text of the WADA 2026 Prohibited List returned no match for "dutasteride", "finasteride" or "reductase" in a word search of the document.10 The list's S5 class, diuretics and masking agents, is worded "Including, but not limited to" and covers "other substances with a similar chemical structure or similar biological effect(s)", so a word search is not a ruling on any substance's status.10 No EMA or TGA document was read, so the status of dutasteride under other regulators is not described here.
Storage and handling
Sources in this part
What is not known
Sources in this part
The label states that the pharmacokinetics of dutasteride in women, in people younger than 18, and across racial and ethnic groups have not been studied or investigated, and that the effect of potent CYP3A4 inhibitors on dutasteride has not been studied.1 Whether the persistence of sexual adverse reactions after stopping is related to dutasteride, and the relationship between long-term use and male breast neoplasia, are listed as unknown on the label.1 The 2019 meta-analysis authors state that studies of dutasteride for male androgenetic alopecia were limited.9 The app's duration figure (1,680 hours, 70 days) is shorter than the label's report that serum concentrations stay above 0.1 ng/mL for up to 4 to 6 months after stopping.1 No randomised comparison of dutasteride with finasteride in BPH or prostate cancer risk was identified among the first 20 records, reviewed by title, of each of two PubMed searches on 16 November 2026.
Frequently asked questions
What is the half-life of dutasteride?
How long does dutasteride stay in the body after stopping?
The Avodart label reports that serum dutasteride concentrations remain detectable, at more than 0.1 ng/mL, for up to 4 to 6 months after stopping treatment.1 The app's duration figure is 1,680 hours (70 days).
What is the bioavailability of dutasteride?
The Avodart label gives absolute bioavailability of approximately 60% (range 40% to 94%) in 5 healthy subjects, and the app lists 60%.1
How long does dutasteride take to reach its peak level?
The label gives the time to peak serum concentration after a single 0.5 mg capsule as within 2 to 3 hours, and the app lists about 2.5 hours.1
How much does dutasteride lower DHT?
What is the difference between dutasteride and finasteride?
The authors of the 2014 hair-loss trial describe dutasteride as a type 1 and 2 5-alpha reductase inhibitor and finasteride as a type 2 inhibitor.2 In that trial dutasteride 0.5 mg was ahead of finasteride 1 mg on hair count at week 24 (P = .003), over 24 weeks in 917 men.2 The trial's registry names GlaxoSmithKline as lead sponsor, three of its nine listed authors are affiliated with GlaxoSmithKline Research & Development, the authors state the study was limited to 24 weeks, and the 0.1 mg dose was not separated from finasteride in the registry's superiority comparison (P 0.56).2,7
What is Avodart (dutasteride) approved for?
What are the side effects of dutasteride?
Guides, tools and comparisons
References
- Waylis Therapeutics LLC. Avodart (dutasteride) soft gelatin capsules. US prescribing information, DailyMed record version 5, 2 November 2026. DailyMed label
- Gubelin Harcha W, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol 2014;70:489-498. PMID 24411083
- Andriole GL, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192-1202. PMID 20357281
- GlaxoSmithKline. REDUCE. ClinicalTrials.gov NCT00056407. NCT00056407
- Roehrborn CG, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010;57:123-131. PMID 19825505
- GlaxoSmithKline. Benign prostatic hyperplasia trial with dutasteride and tamsulosin combination treatment (CombAT). ClinicalTrials.gov NCT00090103. NCT00090103
- GlaxoSmithKline. Dutasteride versus placebo and finasteride in men with androgenetic alopecia. ClinicalTrials.gov NCT01231607. NCT01231607
- Olsen EA, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol 2006;55:1014-1023. PMID 17110217
- Lee S, et al. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis. Acta Derm Venereol 2019;99:12-17. PMID 30206635
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list